Why UTHR so cheap? It should be traded at $$450 instead of $232 currently, because It has patented drugs, earned $5.25 per share last quarter, projects to grow about 20% a year in the forseeble future, with $82 per share net cash.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.